SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001564590-20-045941
Filing Date
2020-10-06
Accepted
2020-10-06 16:41:50
Documents
6
Period of Report
2020-12-01

Document Format Files

Seq Description Document Type Size
1 PRE 14A eypt-pre14a_20201201.htm PRE 14A 385228
2 GRAPHIC g3utnpqgu0z2000005.jpg GRAPHIC 76845
3 GRAPHIC g3utnpqgu0z2000003.jpg GRAPHIC 4629
4 GRAPHIC g3utnpqgu0z2000002.jpg GRAPHIC 2913
5 GRAPHIC g3utnpqgu0z2000001.jpg GRAPHIC 4729
6 GRAPHIC g3utnpqgu0z2000004.jpg GRAPHIC 90131
  Complete submission text file 0001564590-20-045941.txt   634032
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 000-51122 | Film No.: 201227181
SIC: 3826 Laboratory Analytical Instruments